Tradename | Proper name | Company | Number | Date | Products |
---|---|---|---|---|---|
Nutropin AQ | somatropin | Genentech | N-20522 RX | 2008-01-03 | 3 products |
Serostim | somatropin | EMD Serono | N-20604 RX | 1996-08-23 | 3 products |
Humatrope | somatropin | Eli Lilly | N-19640 RX | 1999-02-04 | 3 products |
Zomacton | somatropin | Ferring Pharmaceuticals | N-19774 RX | 2002-01-04 | 2 products |
Norditropin | somatropin | Novo Nordisk | N-21148 RX | 2010-03-01 | 4 products |
Genotropin | somatropin | Pharmacia & Upjohn Company LLC | N-20280 RX | 1995-08-24 | 12 products |
Omnitrope | somatropin | Sandoz | N-21426 RX | 2006-05-30 | 3 products |
Brand Name | Status | Last Update |
---|---|---|
genotropin | Biologic Licensing Application | 2024-08-28 |
humatrope | Biologic Licensing Application | 2024-11-13 |
norditropin | Biologic Licensing Application | 2020-03-09 |
norditropin norditropin nordiflex | 2008-11-10 | |
nutropin aq | 2006-07-11 | |
nutropin aq nuspin 10 nutropin aq nuspin 20 nutropin aq nuspin 5 | Biologic Licensing Application | 2024-11-19 |
nutropin aq nuspin 10 nutropin aq nuspin 20 nutropin aq nuspin 5 nutropin aq pen 10 nutropin aq pen 20 | New Drug Application | 2019-12-17 |
nutropin aq nutropin aq nuspin 10 nutropin aq nuspin 20 nutropin aq nuspin 5 nutropin aq pen 10 nutropin aq pen 20 | New Drug Application | 2013-10-29 |
omnitrope | Biologic Licensing Application | 2024-11-14 |
serostim | Biologic Licensing Application | 2022-02-02 |
Expiration | Code | ||
---|---|---|---|
somatropin, Norditropin, Novo Nordisk Inc. | |||
2114-05-31 | Orphan excl. | ||
somatropin, Humatrope, Eli Lilly and Company | |||
2113-11-01 | Orphan excl. | ||
somatropin, Genotropin, Pharmacia & Upjohn Company LLC | |||
2108-07-25 | Orphan excl. | ||
somatropin, Nutropin, Genentech, Inc. | |||
2103-12-30 | Orphan excl. | ||
somatropin, Serostim, EMD Serono, Inc. | |||
2103-08-23 | Orphan excl. |
Code | Description |
---|---|
J2941 | Injection, somatropin, 1 mg |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Laron syndrome | D046150 | Orphanet_633 | E34.321 | — | 1 | 4 | — | — | 4 |
Endocrine system diseases | D004700 | EFO_0001379 | E34.9 | — | — | 2 | — | — | 2 |
Pituitary dwarfism | D004393 | EFO_1001109 | E23.0 | — | — | 2 | — | — | 2 |
Pituitary diseases | D010900 | — | E23.7 | — | — | 2 | — | — | 2 |
Drug common name | Somatropin |
INN | somatropin |
Description | Accretropin, Genotropin, Humatrope, Norditropin, Nutropin, Nutropin AQ, Omnitrope, Saizen, Serostim, Zomacton, Zorbtive/Serostim, NutropinAq (somatropin) is a protein pharmaceutical. Somatropin was first approved as Accretropin on 2001-02-15. It is used to treat cachexia, dwarfism, heart failure, noonan syndrome, and prader-willi syndrome amongst others in the USA. It has been approved in Europe to treat pituitary dwarfism, prader-willi syndrome, and turner syndrome. The pharmaceutical is active against growth hormone receptor. |
Classification | Protein |
Drug class | tricyclic compounds; growth hormone derivatives; atropine derivatives |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | — |
PDB | — |
CAS-ID | — |
RxCUI | — |
ChEMBL ID | CHEMBL1201621 |
ChEBI ID | — |
PubChem CID | — |
DrugBank | — |
UNII ID | NQX9KB6PCL (ChemIDplus, GSRS) |